NICE has said Biogen's Tysabri can now be used by the NHS in England and Wales to treat highly active relapsing-remitting ...

It will be available as an option for people with relapsing-remitting MS (RRMS), the most common form of the condition which ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.